scholarly journals An Unusual Cause of AKI in a Kidney Transplant Patient with Merkel Cell Cancer

Kidney360 ◽  
2021 ◽  
Vol 2 (12) ◽  
pp. 2040-2041
Author(s):  
Henry H.L. Wu ◽  
Vishnu Jeyalan ◽  
Arvind Ponnusamy
2020 ◽  
Vol 35 (6) ◽  
pp. 899-904 ◽  
Author(s):  
Umberto Maggiore ◽  
Daniel Abramowicz ◽  
Marta Crespo ◽  
Christophe Mariat ◽  
Geir Mjoen ◽  
...  

2000 ◽  
Vol 34 (4) ◽  
pp. 536-536 ◽  
Author(s):  
María Outeda Macías ◽  
Pilar Salvador ◽  
Juan L Hurtado ◽  
Isabel Martín

2021 ◽  
Vol 6 (4) ◽  
pp. S314-S315
Author(s):  
G. GEMBILLO ◽  
F. D'Ignoto ◽  
P. Salis ◽  
D. Santoro ◽  
R. Liotta ◽  
...  

2006 ◽  
Vol 6 ◽  
pp. 412-528 ◽  
Author(s):  
Christine Wu ◽  
Parmjeet Randhawa ◽  
Jerry McCauley

BK virus is ubiquitously present in the latent state in humans, and awareness of the importance of BK polyomavirus is emerging among the kidney transplant community. First discovered in 1971 in the urine of a renal transplant recipient, BK virus nephropathy (BKVN) has come to be recognized as a significant cause of genitourinary disease and potential graft loss in the kidney transplant patient. In this review, we discuss the risk factors, available methods of diagnosis and therapeutic monitoring, and current approaches to therapy of BKVN.


2002 ◽  
Vol 97 (5) ◽  
pp. 751-753 ◽  
Author(s):  
Célia MF Gontijo ◽  
Raquel S Pacheco ◽  
Fernando Oréfice ◽  
Euler Lasmar ◽  
Eduardo S Silva ◽  
...  

2007 ◽  
Vol 7 (2) ◽  
pp. 134-137 ◽  
Author(s):  
Mensura Ašćerić ◽  
Sevleta Avdić ◽  
Sabrija Nukić ◽  
Muamera Vrabac-Mujčinagić

In this work we are going to show results of intensive observation of adverse reactions of cyclosporine therapy during 18 months. The research was applied on 30 patients with kidney transplant. The medium time of kidney transplant survival was 9,7+/-2,3 years, with time span of 6 to 15 years. All the patients were subjects to several years' cyclosporine treatment, which was applied on a daily basis with a dosage of 2 to 5 mg/kg of body weight. The concentration of cyclosporine in blood was measured once a month. The concentration of cyclosporine in blood in 19 patients was in referent values of 122,50 nag/ml up to 280,50 nag/ml of blood. In 4 of the patients the concentration was heightened up to 370 to 538 nag/ml (X=766,37 nag/ml), and in 7 patients cyclosporine was below normal dosage down to 30,78 to 96,30 nag/ml in blood (x=77,12 nag/ml). We noticed these toxic side effects: increased values of systolic and diastolic arterial blood pressure in 5 patients, neurotoxic tremor effects in 4 patients, hyperplasia gingival and hirsute in 1 patient each.


2020 ◽  
pp. 1-4
Author(s):  
Giuseppina Gallucci ◽  
Anna Maria Bochicchio ◽  
Giuseppina Gallucci ◽  
Luigi Cagiano ◽  
Michele Grieco ◽  
...  

Background: Merkel cell carcinoma (MCC) is a rare skin neoplasm first described by Toker in 1972. The tumor usually presents in the sixth to seventh decade of life as a solitary reddish-brown to violaceous subcutaneous nodule on the head, neck, or the extremities. It is seen at an earlier age only in immunocompromised patients like transplant patients in immunosuppressive therapy. Thus, cancer has now become the second cause of death among transplant patients. The tumor growth is rapid in MCC patients, and for metastatic disease, no substantial benefit is obtained by chemotherapy. A new drug has recently become available, an immune checkpoint inhibitor (CPI), avelumab, that is able to delay disease progression significantly. However, there are no current guidelines for the use of immune checkpoint inhibitors in transplant patients. Case Presentation: We describe the case of a 55-year-old kidney transplant patient on immunosuppressive therapy with tacrolimus with an early occurrence of a Merkel cell carcinoma whose aggressive behaviour could not be hampered by Avelumab, due to fear of allograft rejection. Conclusion: CPI therapy is potentially lifesaving in advanced MCC. Further studies are urgently needed to test its benefit in this rapidly expanding field of post-transplant malignancies where there are only a few and less effective therapeutic options.


Sign in / Sign up

Export Citation Format

Share Document